Physician profile
James C Yao
NPI 1962593376
$79,227.18
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 82% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $15K · 2021: $13K · 2022: $3,019 · 2023: $9,081 · 2024: $4,567 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $2,400 · Travel and Lodging: $1,748 · Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,290.00 |
| Honoraria | $2,400.00 |
| Travel and Lodging | $1,748.14 |
| Food and Beverage | $659.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24,709.27 | 2019-2024 | |
| Ipsen Innovation | $13,761.04 | 2019-2022 | |
| Acrotech Biopharma INC. | $9,000.00 | 2023 | Beleodaq |
| Merck Sharp & Dohme LLC | $8,571.22 | 2025 | |
| Chiasma, INC. | $6,600.00 | 2021 | |
| Ipsen Bioscience INC. | $5,400.00 | 2020 | |
| Genzyme Corporation | $4,716.91 | 2024-2025 | |
| Amgen INC. | $2,596.00 | 2021 | |
| Exelixis INC. | $2,510.54 | 2024 | Cabometyx |
| Curium US LLC | $487.60 | 2019 | |
| Medtronic Vascular, INC. | $408.97 | 2019 | |
| Genentech, INC. | $236.85 | 2020-2025 | Tecentriq, Lunsumio |
| Aerin Medical INC. | $123.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.99 | 2023 | |
| Abbott Laboratories | $24.63 | 2025 | Jot Dx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.